Nivolumab and pembrolizumab in the treatment of metastatic melanoma: a retrospective budget impact analysis from the
The increase in reimbursement value, associated with the low adoption of the new immunobiologicals, produced a substantial extra expenditure with drugs prescribed before the incorporation of new technologies, which may represent a burden on the Brazilian health system.
Authors
- Ivan Ricardo Zimmermann (ORCID: https://orcid.org/0000-0001-7757-7519)
- Keitty Regina Cordeiro de Andrade (ORCID: https://orcid.org/0000-0002-8882-6856)
- Ricardo Ribeiro Alves Fernandes (ORCID: https://orcid.org/0000-0002-2197-8724)
Institutions
- Universidade de Brasília (BR)
- Instituto Nacional de Câncer - INCA (BR)
Publication Details
- Journal
- Epidemiologia e Serviços de Saúde
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1590/s2237-96222026v35e20240679.en
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00